HK1202243A1 - Methods for improving cognitive function and decreasing heart rate - Google Patents

Methods for improving cognitive function and decreasing heart rate

Info

Publication number
HK1202243A1
HK1202243A1 HK15102730.4A HK15102730A HK1202243A1 HK 1202243 A1 HK1202243 A1 HK 1202243A1 HK 15102730 A HK15102730 A HK 15102730A HK 1202243 A1 HK1202243 A1 HK 1202243A1
Authority
HK
Hong Kong
Prior art keywords
methods
heart rate
cognitive function
improving cognitive
decreasing heart
Prior art date
Application number
HK15102730.4A
Other languages
English (en)
Chinese (zh)
Inventor
‧尤科-毛羅
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of HK1202243A1 publication Critical patent/HK1202243A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
HK15102730.4A 2009-02-02 2015-03-17 Methods for improving cognitive function and decreasing heart rate HK1202243A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14931009P 2009-02-02 2009-02-02
US18354809P 2009-06-02 2009-06-02

Publications (1)

Publication Number Publication Date
HK1202243A1 true HK1202243A1 (en) 2015-09-25

Family

ID=42041547

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102730.4A HK1202243A1 (en) 2009-02-02 2015-03-17 Methods for improving cognitive function and decreasing heart rate

Country Status (8)

Country Link
US (2) US20100203123A1 (xx)
EP (2) EP2939671A1 (xx)
JP (5) JP2012516852A (xx)
CN (3) CN104042600A (xx)
AU (2) AU2016201382A1 (xx)
CA (1) CA2751275A1 (xx)
HK (1) HK1202243A1 (xx)
WO (1) WO2010088700A1 (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
WO2011006144A1 (en) * 2009-07-10 2011-01-13 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
KR20140057485A (ko) * 2011-05-19 2014-05-13 더 리전츠 오브 더 유니버시티 오브 캘리포니아 인지력 감퇴를 위한 의료식품
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
US20130084272A1 (en) * 2011-09-29 2013-04-04 Philippe Perrin Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
CA2903599A1 (en) * 2013-03-15 2014-09-18 Genspera, Inc. Methods for making cancer compositions
BR112016014262B1 (pt) 2013-12-20 2022-04-05 MARA Renewables Corporation Método para recuperar lipídeos de uma população de micro-organismos
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
JP7101087B2 (ja) * 2018-09-05 2022-07-14 株式会社 伊藤園 軽度認知障害に対する緑茶成分の有効性評価方法
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
AU2020325063A1 (en) * 2019-08-08 2022-03-24 Swinburne University Of Technology Uses of long-chain polyunsaturated fatty acids
JP2024504116A (ja) * 2021-01-15 2024-01-30 ケンブリッジ コグニション リミテッド 周術期神経認知障害及び／又はウイルス感染後認知障害の個人を特定する方法及びシステム
WO2024155781A1 (en) * 2023-01-18 2024-07-25 Bioventures, Llc Method of preventing and treating alzheimer's disease and related dementias with drugs inhibiting the interaction between 14-3-3g protein and hexokinase-1 protein

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
EP2140863A1 (en) * 1993-06-09 2010-01-06 Martek Biosciences Corporation Use of docosahexaenoic acid for the manufacture of a medicament for the treatment of neurological disorders
ATE181745T1 (de) 1994-08-16 1999-07-15 Frische Gmbh Verfahren zur gewinnung von nicht wasserlöslichen, nativen produkten aus nativen stoffgemengen mit hilfe der zentrifugalkraft
WO1996033263A1 (fr) * 1995-04-17 1996-10-24 JAPAN, represented by DIRECTOR-GENERAL OF AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY Nouveaux micro-organismes capables de produire des acides gras hautement insatures et procede de production d'acides gras hautement insatures utilisant ces micro-organismes
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
EP1196518B1 (en) 1999-02-26 2004-08-11 Martek Biosciences Corporation Process for separating a triglyceride comprising a docosahexaenoic acid residue from a mixture of triglycerides
WO2001051598A1 (en) 2000-01-11 2001-07-19 Monsanto Technology Llc Process for making an enriched mixture of polyunsaturated fatty acid esters
MX350779B (es) 2000-01-19 2017-09-18 Dsm Ip Assets B V * Procedimiento de extraccion sin solvente.
DE60140352D1 (de) 2000-04-12 2009-12-17 Gea Westfalia Separator Gmbh Verfahren zur fraktionierung von öl- und polar lipid-enthaltenden rohstoffen unter verwendung von alkohol und zentrifugation
CA2689808A1 (en) 2001-05-14 2002-11-21 Martek Biosciences Corporation Production and use of a polar lipid-rich fraction containing stearidonic acid and gamma linolenic acid from plant seeds and microbes
AU2002309856B2 (en) 2001-05-14 2008-10-23 Dsm Ip Assets B.V. Production and use of a polar lipid-rich fraction containing omega-3 and/or omega-6 highly unsaturated fatty acids from microbes, genetically modified plant seeds and marine organisms
AU2002320251A1 (en) * 2001-07-05 2003-01-21 Vital Basics, Inc. Compositions for improving mental performance
ES2391381T3 (es) 2002-05-03 2012-11-23 Martek Biosciences Corporation Lípidos de alta calidad y métodos para su producción mediante liberación enzimática a partir de biomasa
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
JP5503846B2 (ja) * 2005-01-24 2014-05-28 プロノヴァ・バイオファーマ・ノルゲ・アーエス アミロイドーシス関連疾患の治療のための医療品又は食料品の製造における、ｄｈａを含有する脂肪酸組成物の使用
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
PL1888081T3 (pl) * 2005-05-23 2017-07-31 Massachusetts Institute Of Technology Kompozycje zawierające PUFA i sposoby ich zastosowania
CN103211807A (zh) * 2005-07-08 2013-07-24 Dsmip资产公司 用于治疗痴呆和前痴呆相关病症的多不饱和脂肪酸
WO2009002145A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving function of brain functioning
AU2008269989B2 (en) * 2007-06-29 2014-02-27 Dsm Ip Assets B.V. Production and purification of esters of polyunsaturated fatty acids
WO2011006144A1 (en) * 2009-07-10 2011-01-13 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid

Also Published As

Publication number Publication date
CN108324706A (zh) 2018-07-27
JP2015143248A (ja) 2015-08-06
AU2016201382A1 (en) 2016-03-24
CN102365087A (zh) 2012-02-29
WO2010088700A1 (en) 2010-08-05
JP2020050675A (ja) 2020-04-02
JP2012516852A (ja) 2012-07-26
CN104042600A (zh) 2014-09-17
AU2010207929A1 (en) 2011-09-22
US20100203123A1 (en) 2010-08-12
EP2939671A1 (en) 2015-11-04
JP2018104477A (ja) 2018-07-05
AU2017245327A1 (en) 2017-11-02
JP2022059063A (ja) 2022-04-12
EP2391361A1 (en) 2011-12-07
CA2751275A1 (en) 2010-08-05
US20130172412A1 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
HK1202243A1 (en) Methods for improving cognitive function and decreasing heart rate
GB2494493B (en) Patient interface and aspects thereof
GB2482092B (en) Patient interface and aspects thereof
GB2530946B (en) Patient interface and headgear
EP2611496A4 (en) Methods of Treatment
EP2556799A4 (en) PROCESS FOR PRODUCING TISSUE CLIPS, AND CLIPPER FOR TISSUE
EP2561072A4 (en) NANOZYMES, PROCESSES FOR PRODUCING NANOZYMES, AND METHODS OF USING NANOZYMES
EP2578153A4 (en) AUDIOMETER AND ASSOCIATED METHOD
IL214133A0 (en) Skin treatment
GB0918392D0 (en) Diagnostic and therapeutic methods
PT2630475T (pt) Método de diagnóstico e tratamento
GB0912744D0 (en) Methods and uses
EP2470022A4 (en) COMPOUNDS AND METHODS
GB2467764B (en) Attachment means and methods
GB0909380D0 (en) Method and use
EP2654742A4 (en) PROCESS FOR IMPROVING COGNITIVE FUNCTION
GB0903348D0 (en) Compounds and methods relating thereto
EP2496143A4 (en) HEART RATE MONITOR
EP2440238A4 (en) Methods of Treatment
IL220242A0 (en) Methods of improving cognitive functions
GB201013139D0 (en) An improved bed and bath
GB201008694D0 (en) An improved bed and bath
GB201018097D0 (en) Diagnostic method and treatment
GB0920904D0 (en) Uses and methods